10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

BEAM News
Member News
Events

Latest news of BEAM Alliance

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

02 April 2020 - BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

To support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

page 1/4

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

14 October 2020 - Polyphor Ltd

Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program

We are encouraged by the progress we have made in implementing Polyphor’s renewed strategy to advance our pipeline in oncology…

13 October 2020 - Nabriva Therapeutics GmbH

Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for administration in humans discovered and developed by the Nabriva Therapeutics team.…

29 September 2020 - Aptorum Group Ltd

Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome

RPIDD is an innovative liquid biopsy-driven rapid pathogen molecular diagnostics technology with proprietary and patented technologies being developed to deplete…

21 September 2020 - Alaxia

Alaxia breaks new ground with lead compound ALX‑009 as virucidal agent

ALX-009 targets antibiotic-multi-resistant Gram negative bacteria (‘super bugs’) that are currently untreatable. It combines two endogenous substances: the hypothiocyanite ion…

10 September 2020 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

01 September 2020 - Aptorum Group Ltd

Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel first-in-class small molecule developed in oral form…

page 1/22

Events

17 November 2020

REVIVE Webinar: Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)

In this webinar, the speakers will give an overview of their work on the discovery of antibiotics through the use…

26 October 2020

BIO-Europe® 2020 Digital – 26th Annual International Partnering Conference

The 26th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe, though in 2020 by necessity we…

21 October 2020

REVIVE Webinar: Building better breakpoints: data and methods needed to determine breakpoints for new agents

In this webinar, John Turnidge and Anouk Muller will discuss how to determine breakpoints for new agents. The following topics…

08 October 2020

tranScrip: COVID-19 Panel Discussion: How to optimise clinical trial and regulatory outcomes after COVID-19 disruption

During this hour-long panel discussion, we will explore the strategic and operational risks that have, and continue to, materialise in…

08 October 2020

REVIVE Webinar: Exploring safety issues in antimicrobial drug development

This webinar was developed in collaboration with CARB-X, JPIAMR, REPAIR Impact Fund, Wellcome Trust, ASM and ESCMID. It is part…

24 September 2020

REVIVE Webinar: Moving from preclinical to clinical-stage: Challenges and opportunities

This webinar was developed in collaboration with CARB-X, JPIAMR, REPAIR Impact Fund, Wellcome Trust, ASM and ESCMID. It is part…

21 September 2020

BioPharm America™ 2020 Digital —13th Annual International Partnering Conference

For this year’s digital event, BioPharm America will focus on Innovation and Investing, with the added collaboration of a number…

25 August 2020

ChinaBio ® Partnering Forum 2020 Digital

ChinaBio® Partnering Forum is the largest and most productive China-focused life science partnering event. To be held as a digital…

24 August 2020

4th AMR Conference Novel Antimicrobial & AMR Diagnostics – Delivered Digitally

In view of the continuing uncertain situation and travel restrictions due to the COVID-19 pandemic, we have decided to implement…

page 1/8